Growing Use of Bispecifics for the Treatment of Multiple Myeloma

George Nahas, DO, attending physician, and hematology and oncology specialist at Miami Cancer Institute, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.

In recent years, chimeric antigen receptor (CAR) T cells and bispecific T-cell engagers have become available for the treatment of patients with multiple myeloma. However, they are utilized in later lines of therapies. Since they are newer developments, questions remain regarding how to use them, when to use them, and more.

As the field continues to evolve and more options become available for patients with multiple myeloma, Nahas notes that CAR T-cell therapies and bispecifics will likely be moved up into the earlier lines of therapy, even as early as in the second-line setting.

Transcription:

0:10 | The reason why I think it is important to mention bispecific trials is because not only do we have the MajesTEC trials demonstrating a similar patient population of patients who are relapsed or refractory with later lines of therapy, these are patients who are refractory to the most recent therapy as well, these patients also had a great overall response rate of 60 plus percent, with CR rates as high as 40% or so percent. We have a BCMA bispecific, but are there other bispecifics that we can combine too?

0:56 | Recent data at ASCO also demonstrated that combining 2 biospecifics did have an overwhelmingly amazing overall response rate of up to 90 plus percent. That is going to be something moving forward. Can we combine bispecific T-cell engagers?

1:19 | The other question is, when we have to use bispecifics for CAR T, how early can we use them? These are important research points that are certainly being studied now and they'll give us a lot of information in the future on how to treat our patients.